Furthermore, obvious amelioration in dyslipidemia (lower triglycerides, total cholesterol and higher HDL) and decreased inflammatory markers (TNF-α and IL6) levels have been noticed after administration of AD-MSCs treated with OXA. The gene discussed is IL6; the disease is Alzheimer disease.